Work mix: 100% prime · 0% sub · primary NAICS 325412 / PSC 6505 DRUGS AND BIOLOGICALS
101% of Elusys Therapeutics’s obligations are not openly competed — these contracts typically renew with the incumbent rather than going to recompete.
Track this company in SCOUT →Largely sole-source — these contracts typically renew with Elusys Therapeutics rather than being openly recompeted.
No incumbent recompetes detected in the next 24 months.
No incumbent recompetes detected in the next 24 months.
Live recompete scoring, competitive landscape, and alerts on Elusys Therapeuticsin SCOUT. Free — no card required.
Others competing in Elusys Therapeutics's NAICS lane — open a profile to compare footprint and recompetes.
Browse live recompete landscapes by vehicle, agency, and set-aside.
Submit your UEI and we’ll generate your federal profile. We’ll email you when it’s live.
Query this company live in SCOUT via MCP — personalized displacement scoring, alerts, and capture workflow. Learn about SCOUT MCP →
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Register free to start exploring SCOUT →